REGENXBIO and Abbvie announce a collaboration to co-develop RGX-314 for the treatment of wet AMD, diabetic retinopathy and other chronic retinal diseases. This massive announcement puts a lot of resources behind the commercialization efforts of RGX-314 in anticipation of an eventual approval. In the short-term, $RGNX benefits from a large upfront payment as well as upcoming milestone payments. $RGNX/$CLSD are about to announce Cohort 1 data from their SCS wet AMD trial, which if positive, will be very bullish for the company. I talk about what I’m looking forward to here.
As we approach Q4, a number of interesting oncology companies are set to provide updates in their clinical programs. Companies I have my eye on are: $ONCT, $CRIS, $BTAI and $PDSB and in this video, I discuss where they are in their programs and how I feel about them as potential investments.
$RGNX/$CLSD/$ABBV – 1:05
$APLS – 7:30
$ONCT – 15:20
$CRIS – 21:28
$BTAI – 26:00
$PDSB – 32:29
Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech
Follow me on twitter @matthewlepoire
Send me an email firstname.lastname@example.org
Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech